bullish
Jacobio: Updated Valuation and Other Thoughts
409 Views04 Dec 2020 08:29
This Insight updates our NPV (reduce by ~US$100MM) of Jacobio, analyzes the use of proceeds, and has a list of 2021 events. We will give our opinion of the deal in a future Insight closer to pricing.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Kemp Dolliver, CFA
Founder
- China Healthcare: Macro Themes18 Dec 2020
- Jacobio: Management Solves for Valuation10 Dec 2020
- Jacobio Pharma IPO Initiation: Drugging the Undruggable05 Dec 2020
- Jacobio: Updated Valuation and Other Thoughts04 Dec 2020
- Jacobio Pharma: More Thinking on Valuation21 Nov 2020
- Jacobio Pharma: Focus on Novel Targets21 Oct 2020
- Jacobio (加科思药业) Pre-IPO: Right Team but Long Time to Market14 Oct 2020
x